Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
The new trial lasted as long but involved 1,613 adults with obesity and co-existing type 2 diabetes
Retatrutide (LY3437943) is Eli Lillys experimental triple-agonist drug that activates: GLP-1 (Glucagon-like peptide-1) reduces appetite and slows digestion GIP (Glucose-dependent insulinotropic peptide) enhances insulin sensitivity Glucagon receptor increases fat metabolism and energy expenditure In phase-2 trials, Retatrutide achieved up to 24% body-weight reduction rivaling or even surpassing bariatric surgery outcomes
This trial was done on individuals aged 20 to 65 with visceral fat areas exceeding 90 cm
10.1016/S0042-6989(96)00222-2 50 ParkJ
Why should they be used carefully
